Literature DB >> 16947781

Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components.

Daniel Aletaha1, Josef Smolen, Michael M Ward.   

Abstract

OBJECTIVE: Measurement of physical function at one point in time cannot distinguish impairment caused by the active disease process from chronic irreversible impairment. We aimed to dissect these two components of functional limitation in rheumatoid arthritis (RA) by using the disability index of the Health Assessment Questionnaire (HAQ) as the measure of function.
METHODS: We performed a secondary analysis of data from 6 contemporary clinical trials of RA (2,763 patients). Patients in whom remission was achieved in the trials, based on a simplified disease activity index, were identified. In an individual patient, HAQ scores at trial entry represented both reversible and irreversible impairments, while HAQ scores at the time of RA remission represented the mostly irreversible component, and the difference between these corresponded to the component related to disease activity. We tested the concept that the HAQ has a reversible and an irreversible component by associating the HAQ score during remission with 2 measures associated with the degree of accrued damage: duration of RA and radiographic severity.
RESULTS: Among patients in whom clinical remission was achieved (n = 295), average HAQ scores despite clinical remission increased progressively with the duration of RA, from 0.19 (<2 years of RA) to 0.36 (2-<5 years) to 0.38 (5-<10 years) to 0.55 (>/=10 years) (P < 0.001). The reversibility of HAQ scores decreased with the duration of RA (median 100%, 83.3%, 81.9%, and 66.7%, respectively; P < 0.001). Findings were similar in patients subgrouped by quartile of radiographic scores.
CONCLUSION: Differences in the sources of functional limitations should be considered in the interpretation of functional measures, and in their use for prediction and in cost analyses.

Entities:  

Mesh:

Year:  2006        PMID: 16947781     DOI: 10.1002/art.22052

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  74 in total

1.  Intra-individual assessment of inflammatory severity and cartilage composition of finger joints in rheumatoid arthritis.

Authors:  C Schleich; A Müller-Lutz; P Sewerin; B Ostendorf; C Buchbender; M Schneider; G Antoch; F Miese
Journal:  Skeletal Radiol       Date:  2014-11-01       Impact factor: 2.199

2.  Assessment of the treat-to-target strategy in patients with refractory rheumatoid arthritis. A prospective study on efficacy and safety in a Saudi population.

Authors:  R H A Mohammed; H H Kewan; M Bukhari
Journal:  Z Rheumatol       Date:  2014-10       Impact factor: 1.372

Review 3.  Joint remodelling in inflammatory disease.

Authors:  Georg Schett
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

4.  [Austrian expert opinion on the standard for expert assessment of course of illness in patients with chronic polyarthritis (rheumatoid arthritis)].

Authors:  Klaus P Machold; Hans Peter Brezinsek; Burkhard F Leeb; Stephan Pflugbeil; Franz Rainer; Franz Singer; Martin Skoumal; Tanja A Stamm; Manfred Herold
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

5.  Clinically important changes in short form 36 health survey scales for use in rheumatoid arthritis clinical trials: the impact of low responsiveness.

Authors:  Michael M Ward; Lori C Guthrie; Maria I Alba
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-12       Impact factor: 4.794

6.  Creative trial design in RA: optimizing patient outcomes.

Authors:  Maya H Buch; Sue Pavitt; Mahesh Parmar; Paul Emery
Journal:  Nat Rev Rheumatol       Date:  2013-02-05       Impact factor: 20.543

Review 7.  What is the clinical relevance of erosions and joint space narrowing in RA?

Authors:  Siri Lillegraven; Désirée van der Heijde; Till Uhlig; Tore K Kvien; Espen A Haavardsholm
Journal:  Nat Rev Rheumatol       Date:  2012-01-17       Impact factor: 20.543

Review 8.  [Rheumatoid arthritis. Target outcome for treatment].

Authors:  D Aletaha; J Smolen
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

9.  Association of body composition with disability in rheumatoid arthritis: impact of appendicular fat and lean tissue mass.

Authors:  Jon T Giles; Susan J Bartlett; Ross E Andersen; Kevin R Fontaine; Joan M Bathon
Journal:  Arthritis Rheum       Date:  2008-10-15

10.  Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.

Authors:  J Smolen; R B Landewé; P Mease; J Brzezicki; D Mason; K Luijtens; R F van Vollenhoven; A Kavanaugh; M Schiff; G R Burmester; V Strand; J Vencovsky; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2008-11-17       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.